Myovant Science Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Myovant science phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Myovant Science Phase Today - Breaking & Trending Today

Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
•LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline •Achieved six of seven key secondary endpoints including reduction of pain •Bone mineral density maintained at levels comparable to placebo •Data were included in U.S. New Drug Application for relugolix combination tablet for uterine fibroids
February 17, 2021 20:02 ET
| Source:
Sumitovant Biopharma
Sumitovant Biopharma
New York, New York, UNITED STATES
New York, London, Feb. 17, 2021 (GLOBE NEWSWIRE) Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that the ....

New York , United States , City Of , United Kingdom , Sumitomo Dainippon Pharma , Sumitovant Biopharma , Mary Stutts Sumitovant Biopharma , Myrtle Potter , Juan Camilo Arjona Ferreira , Myovant Sciences Forward , Myovant Sciences , Dainippon Pharmaceutical Co Ltd , Altavant Sciences , Exchange Commission , Spirovant Sciences , Myovant Sciences Inc , European Union , Sumitomo Dainippon Pharma Co Ltd , Urovant Sciences , Sumitomo Pharmaceuticals Co Ltd , Sumitovant Biopharma Ltd , Biopharma Ltd , New England Journal , Myovant Science Phase , Chief Medical Officer , Pelvic Discomfort ,

Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant .
Sumitovant BiopharmaFebruary 18, 2021 GMT
New York, London, Feb. 17, 2021 (GLOBE NEWSWIRE) Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that the New England Journal of Medicine published Myovant Sciences’ Phase 3 LIBERTY 1 and LIBERTY 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with uterine fibroids. As previously reported, both studies achieved the primary endpoint of response rates in menstrual blood loss in addition to six of the seven key secondary endpoints, while maintaining bone mineral density comparable to placebo as part of a well-tolerated safety profile over 24 weeks. ....

New York , United States , City Of , United Kingdom , Sumitomo Dainippon Pharma , Sumitovant Biopharma , Mary Stutts Sumitovant Biopharma , Myrtle Potter , Myovant Sciences Forward , Myovant Sciences , Dainippon Pharmaceutical Co Ltd , Exchange Commission , Altavant Sciences , Spirovant Sciences , European Union , Sumitomo Dainippon Pharma Co Ltd , Urovant Sciences , Sumitomo Pharmaceuticals Co Ltd , Sumitovant Biopharma Ltd , Biopharma Ltd , New England Journal , Myovant Science Phase , New York City , Sumitomo Dainippon , Enzyvant Therapeutics , Dainippon Pharma ,

UPDATE: Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis

•84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year •Data to be included in New Drug Application submission to U.S. Food and Drug Administration anticipated in first half of 2021 ....

New York , United States , City Of , United Kingdom , Sumitomo Dainippon Pharma , Sumitovant Biopharma , Mary Stutts Sumitovant Biopharma , Myrtle Potter , Juan Camilo Arjona Ferreira , Myovant Sciences Forward , American Society For Reproductive Medicine , Drug Administration , Myovant Sciences , Dainippon Pharmaceutical Co Ltd , Exchange Commission , Myovant Sciences Inc , European Union , Sumitomo Dainippon Pharma Co Ltd , Virtual Congress , Sumitomo Pharmaceuticals Co Ltd , Sumitovant Biopharma Ltd , Program In Endometriosis , Biopharma Ltd , Myovant Science Phase , New Drug Application , Chief Executive Officer ,

UPDATE: Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
UPDATE: Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 .
Sumitovant BiopharmaJanuary 26, 2021 GMT
NEW YORK, LONDON,, Jan. 26, 2021 (GLOBE NEWSWIRE) Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences’ Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over one year (52 weeks) with minimal and stable bone mineral density loss. The dat a are consistent with the efficacy and safety profile observed through 24 weeks in the Phase 3 SPIRIT 1 and SPIRIT 2 studies. These results will be included in the New Drug Applicat ....

New York , United States , City Of , United Kingdom , Sumitomo Dainippon Pharma , Sumitovant Biopharma , Mary Stutts Sumitovant Biopharma , Myrtle Potter , Juan Camilo Arjona Ferreira , Myovant Sciences Forward , American Society For Reproductive Medicine , Drug Administration , Myovant Sciences , Dainippon Pharmaceutical Co Ltd , Exchange Commission , Myovant Sciences Inc , European Union , Sumitomo Dainippon Pharma Co Ltd , Virtual Congress , Sumitomo Pharmaceuticals Co Ltd , Sumitovant Biopharma Ltd , Program In Endometriosis , Biopharma Ltd , Myovant Science Phase , New Drug Application , Chief Executive Officer ,